In the US, about one million people with diabetes per year are treated for foot ulcers.

Current treatment involves the use of various skin substitutes which are able to improve wound healing in the short term but have limited long-term success due to the lack of blood vessels to deliver enough oxygen and nutrients.

Angioblast plans to develop an MPC product on a biocompatible patch which will be the only product in the market capable of providing both increased blood supply and new cells to repair and regenerate the wound site.

The Technology

 

Last Share Price

22 January - RBS Equities Research: Mesoblast - Analysis of MSB’s Opportunities

8 January - Southern Cross Equities Research: Mesoblast – The Stem Cell Opportunity

December 22 - RBS Equities Research: Diabetes - An Expanding Portfolio

December 21 - Mesoblast - National Electronic Media Coverage

30 March 2009 - RBS Equities Research

17 March 2009 - Lodge Partners Research Report

27 February 2009 - ABN AMRO Equity Research

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine